Marinus Pharmaceuticals said the FDA has approved Ztalmy oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder.
- It is expected to be available through a designated specialty pharmacy in July 2022
To view the source of this information, click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2022 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.